Neoantigens and antibodies to factor VIII

Prowse, 1994, Kill and cure: the hope and reality of virus inactivation, Vox Sang, 67, 191, 10.1111/j.1423-0410.1994.tb04574.x Mannucci, 1994, Transmission of hepatitis A to patients with haemophilia by Factor VIII concentrates treated with organic solvent and detergent to inactivate viruses, Ann Int Med, 120, 1, 10.7326/0003-4819-120-1-199401010-00001 Azzi, 1993, Human Parvovirus B19 infection in haemophiliacs first infused with two high purity, virally attenuated Factor VIII concentrates, Am J Haematol, 39, 228, 10.1002/ajh.2830390315 Rosendaal, 1993, A sudden increase in Factor-VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands, Blood, 81, 2180, 10.1182/blood.V81.8.2180.2180 Peerlink, 1993, A higher than expected incidence of Factor-VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized Factor-VIII concentrate, Thromb Haemost, 69, 115, 10.1055/s-0038-1651565 Peerlinck, 1987, Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated inactivated plasma derived Factor VIII concentrate, Thromb Haemost, 77, 80 Josic, 1997, Degradation products of factor VIII which can lead to increased immunogenicity, Thromb Haemost, 576 Konrad, 1987, Assessment of the antigenic response in humans to recombinant mutant interferon beta, J Clin Immunol, 7, 365, 10.1007/BF00917014 Nilsson, 1990, Non-coagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients, Blood, 75, 378, 10.1182/blood.V75.2.378.378 Oldenburg, 1997, HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII, Thromb Haemost, 77, 238, 10.1055/s-0038-1655945 Schwaab, 1995, Haemophilia A: mutation type determines risk of inhibitor formation, Thromb Haemost, 74, 1402, 10.1055/s-0038-1649954 Brief, 1994, Inhibitors in haemophilia A: are some products safer?, Semin Hematol, 31, 11 White, 1997 Scharrer, 1993, Incidence of inhibitors in haemophiliacs: a review of the literature, Blood Coag Fibrinolysis, 4, 753, 10.1097/00001721-199310000-00012 Yee, 1997, Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product, Thromb Haemost, 78, 1027, 10.1055/s-0038-1657681 United Kingdom Haemophilia Directors, 1997, Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders, Haemophilia, 3, 63, 10.1046/j.1365-2516.1997.00073.x Cleland, 1993, The development of stable protein formulations — a close look at protein aggregation, deamidation, and oxidation, Crit Rev Ther Drug Carr Syst, 10, 307 Kasper, 1991, Laboratory tests for Factor-VIII inhibitors, their variation, significance and interpretation, Blood Coag Fibrinol, 2, 7 Scandella, 1995, Some factor VIII inhibitor antibodies recognise a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site, Blood, 86, 1811, 10.1182/blood.V86.5.1811.bloodjournal8651811 Palmer, 1997, Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays, Vox Sang, 72, 148, 10.1046/j.1423-0410.1997.7230148.x Barrowcliffe, 1997, Modification of FVIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation, Thromb Haemost, 576 Di Giambattista, 1997, Sensitive western blotting method for monitoring FVIII degradation in FVIII concentrates, Thromb Haemost, 511 Brackmann, 1996, Immune tolerance for the treatment of factor VIII inhibitors — Twenty years ‘Bonn protocol’, Vox Sang, 70, 30, 10.1111/j.1423-0410.1996.tb01346.x Sultan, 1995, Inhibitor development in haemophiliacs: Theoretical background and clinical aspects, Blood Coag Fibrinol, 6, S55, 10.1097/00001721-199506002-00012 Desqueper, 1995, Cohn's fractions as a source of anti-factor VIII and corresponding antiidiotypic antibodies for possible therapeutic purposes of haemophilia A patients with inhibitors, Thromb Haemost, 73, 1011 Prowse, 1981, Changes in Factor VIII complex activities during production of a clinical intermediate purity Factor VIII concentrate, Thromb Haemost, 46, 597, 10.1055/s-0038-1653426 Esmon, 1990, Characterisation of recombinant Factor VIII and a recombinant Factor VIII deletion mutant using a rabbit immunogenicity model system, Blood, 76, 1593, 10.1182/blood.V76.8.1593.1593 Lind, 1995, Novel forms of B-domaindeleted recombinant factor VIII molecules—construction and biochemical characterisation, Eur J Biochem, 282, 19, 10.1111/j.1432-1033.1995.tb20776.x MacGregor, 1995, No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concentrates, Vox Sang, 69, 319, 10.1111/j.1423-0410.1995.tb00367.x Gilles, 1997, Heating lyophilised factor VIII does not alter its recognition by specific antibodies, Vox Sang, 73, 16, 10.1046/j.1423-0410.1997.7310016.x Winkelman, 1996, Evidence of enhanced potential antigenicity after heat treatment of high purity factor VIII concentrate in solution Dawes, 1990, High molecular weight aggregate content of heated and unheated factor VIII products determined by fast-protein liquid chromatography, Vox Sang, 58, 30, 10.1111/j.1423-0410.1990.tb02051.x Schwinn, 1994, A solvent/detergent treated pasteurised and highly purified Factor VIII concentrate, Arzneimittelforschung, 44, 188 Dazzi, 1995, An animal model to explore the molecular basis of factor VIII (FVIII) inhibitor formation: evidence of an anti-FVIII T-cell response and importance of administration route, Thromb Haemost, 73, 1026 Arrighi, 1995, In vitro and in animal studies on a double virus inactivated factor VIII concentrate, Thromb Haemost, 74, 868, 10.1055/s-0038-1649839 Pittman, 1993, Biochemical, immunological and in vivo functional characterization of B-domain-deleted Factor-VIII, Blood, 81, 2925, 10.1182/blood.V81.11.2925.2925 Sanjawala, 1991, Transgenic mice containing the human Factor VIII gene: model for immunogenicity evaluation, Thromb Haemost, 65, 943 Sauger, 1995, Immunogenicity of a recombinant deleted factor VIII compared to the plasmaderived factor VIII in the model of humanised SLID mice, Thromb Haemostas, 73, A1201 Vanzieleghem, 1997, In vivo production of functional anti-factor VIII antibodies in severe combined immunodeficient (SCID) mice reconstituted with PBL of healthy blood donors, Thromb Haemost, 590 Jacquemin, 1997, Production of human monoclonal anti-FVIII IgG antibodies by immortalisation of memory B lymphocytes from haemophilia A patients with inhibitors, Thromb Haemost, 162 Committee for Proprietary Medicinal Products, 1996, Note for guidance to assess efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophilia, before and after authorisation CPMP/198/95, Eur Agency for the Evaluation of Medicinal Products